Acute severe community-acquired pneumonia: comprehensive ICU pathway (sepsis, ARDS, empiric therapy, corticosteroids)

Severity scores for community-acquired pneumonia

Score	Components	Scoring	Decision threshold
CURB-65 (Lim 2003)	Confusion, Urea >7 mmol/L, Respiratory rate >=30, Blood pressure (<90 systolic or <=60 diastolic), age >=65	1 point each (0-5)	0-1 home; 2 consider admission; >=3 hospital, consider ICU; 4-5 severe, ICU
CRB-65 (no bloods)	Confusion, RR >=30, BP <90/60, age >=65	1 point each (0-4)	0 home; >=1 consider admission; >=2 severe (use pre-hospital, no urea needed)
PSI / PORT (Fine 1997)	Demographics (age, sex, nursing home), comorbidity (neoplastic/liver/CHF/cerebrovascular/renal disease), exam (altered mental status, RR >=30, systolic <90, temp <35 or >=40, pulse >=125), labs + imaging (pH <7.35, BUN >=11, Na <130, glucose >=14, haematocrit <30, PaO2 <60, pleural effusion)	Points -> 5 classes (I-V)	I-II outpatient (low mortality <1%); III ward (observe brief inpatient); IV-V hospital (mortality 8.9-29.2%)
IDSA/ATS 2007 (severe CAP criteria)	MAJOR: need invasive mechanical ventilation OR septic shock. MINOR: RR >=30, PaO2/FiO2 <250, multilobar infiltrates, confusion/disorientation, BUN >=20 mg/dL (~7 mmol/L), WBC <4, platelets <100, hypothermia <36, hypotension needing aggressive fluids	Count met criteria	1 major OR >=3 minor = severe CAP -> ICU admission
SMART-COP (ANZ)	Systolic BP <90, Multilobar, Albumin <35, RR (age-adjusted), Tachycardia >=125, Confusion, Oxygen (PaO2 <70 or O2 sat <=93%), pH <7.35	Score	Low vs high-intensity (ICU) — validated in Australian cohort

[1]

Empiric antibiotic regimens for severe CAP (IDSA/ATS 2019)

Scenario	First-line	Alternative	Key points
Severe CAP, ICU (no risk factors)	Ceftriaxone 2g IV daily + azithromycin 500mg IV daily	Ampicillin-sulbactam 3g IV q6h + azithromycin; OR beta-lactam + moxifloxacin/levofloxacin	Cover S. pneumo + H. influenzae (beta-lactam) + atypicals — Legionella/Mycoplasma/Chlamydia (macrolide or respiratory FQ)
Beta-lactam allergy	Moxifloxacin 400mg IV daily + azithromycin	Levofloxacin 750mg + azithromycin	Respiratory FQ covers typical + atypical (azithromycin adds Legionella/atypical synergy)
Pseudomonas risk (bronchiectasis, prior isolation, recent hospitalisation, severe structurally-diseased lung)	Pip-tazo 4.5g IV q6h + ciprofloxacin 400mg IV q12h (+ azithromycin for atypicals)	Cefepime 2g q8h + ciprofloxacin; OR anti-pseudomonal beta-lactam + aminoglycoside + azithromycin/levofloxacin	DUAL anti-pseudomonal + atypical cover; ceftriaxone does NOT cover Pseudomonas
MRSA risk (post-inflfluenza, cavitary, recent hospitalisation, ESRD, IVDU, prior MRSA)	ADD vancomycin 15-20mg/kg q8-12h (AUC 400-600) to standard severe CAP regimen	ADD linezolid 600mg IV BD (better lung penetration; if vancomycin nephrotoxicity)	Add to standard cover; linezolid preferred by some for necrotising MRSA (toxin suppression)
Aspiration suspected	Ampicillin-sulbactam (covers anaerobes) + azithromycin; OR add metronidazole/clindamycin to standard regimen	Meropenem (covers anaerobes + Gram-negatives)	Add anaerobic cover; clindamycin preferred for lung abscess
Influenza season / suspected influenza	ADD oseltamivir 75mg BD to standard regimen (within 48h; earlier better)	(IV peramivir if unable PO)	Start empirically if influenza suspected — do NOT wait for PCR; always add MRSA cover if post-influenza deterioration

[1]

Severe CAP comprehensive ICU management pathway (hour-1 through discharge)

RECOGNISE SEVERITY + ICU TRIAGE — Apply a severity score at presentation: (a) CURB-65 — >=3 = severe, consider ICU; 4-5 = ICU; (b) PSI/PORT — class IV-V high-risk hospital, class V ICU; (c) IDSA/ATS 2007 severe CAP criteria — 1 MAJOR (invasive mechanical ventilation OR septic shock needing vasopressors) OR >=3 MINOR criteria (RR >=30, PaO2/FiO2 <250, multilobar infiltrates, confusion, BUN >=20, WBC <4, platelets <100, temp <36, hypotension needing aggressive fluids) = severe CAP -> ICU. SEPSIS-3: CAP with organ dysfunction (SOFA >=2, lactate >2, MAP <65 after fluids, etc.) = SEPSIS; lactate >2 after fluids + vasopressor need = SEPTIC SHOCK. Recognise ARDS risk early (bilateral infiltrates + PaO2/FiO2 <300 within 1 week of pneumonia).
HOUR-1 SEPSIS BUNDLE (do NOT delay antibiotics for cultures) — (a) LACTATE: baseline; repeat at 2-4h if >2 mmol/L; >4 = severe sepsis/perfusion defect. (b) BLOOD CULTURES x2 (peripheral, before antibiotics if possible but NEVER delay antibiotics >1h); positive in 10-20% (bacteraemic pneumococcal CAP worse prognosis). (c) RESPIRATORY SAMPLES: sputum Gram stain + culture (good-quality: >25 PMN, <10 epithelial/hpf); endotracheal aspirate if intubated; consider BAL/mini-BAL if intubated + not responding. (d) URINARY ANTIGENS: pneumococcal + Legionella serogroup 1 (rapid — high yield in severe CAP, Legionella a classic severe-CAP pathogen). (e) VIRAL PCR: multiplex respiratory panel — influenza A/B, SARS-CoV-2, RSV (rapid; start oseltamivir empirically if influenza suspected in season). (f) ANTIBIOTICS WITHIN 1 HOUR (sepsis hour-1 bundle) — broad-spectrum empiric covering typical + atypical; each hour delay in shock -> ~4-8% mortality rise. (g) FLUIDS: 250-500 mL crystalloid boluses if hypovolaemic/hypotensive, reassess; goal MAP >=65, urine >0.5 mL/kg/h, lactate falling; avoid overload (worsens ARDS — CLASSIC/CLOVERS support a more restrictive approach; ~1.5-3 L in first 3h). (h) VASOPRESSORS: noradrenaline first-line if MAP <65 after fluids; add vasopressin then adrenaline; target MAP >=65. (i) CATHETERISE (monitor urine output).
EMPIRIC ANTIBIOTIC THERAPY (within 1 hour) — (a) STANDARD SEVERE CAP/ICU: beta-lactam (ceftriaxone 2g IV daily, cefotaxime, or ampicillin-sulbactam 3g IV q6h) + MACROLIDE (azithromycin 500mg IV daily) OR beta-lactam + respiratory fluoroquinolone (moxifloxacin 400mg IV daily or levofloxacin 750mg). Rationale: beta-lactam covers typical (S. pneumoniae #1, H. influenzae, Moraxella); macrolide/FQ covers atypicals (Legionella, Mycoplasma, Chlamydia) — Legionella is a leading cause of SEVERE CAP, must be covered. (b) PSEUDOMONAS RISK (bronchiectasis, prior Pseudomonas within 1 yr, recent hospitalisation/antibiotics, severe bronchiectatic/structurally-diseased lung): anti-pseudomonal beta-lactam (pip-tazo 4.5g IV q6h, cefepime 2g IV q8h, or meropenem 1g IV q8h) + EITHER ciprofloxacin 400mg IV q12h OR aminoglycoside (gentamicin/tobramycin) + azithromycin or levofloxacin (atypical cover). DUAL anti-pseudomonal + atypical. (c) MRSA RISK (post-influenza, cavitary infiltrates, recent hospitalisation, ESRD/dialysis, prior MRSA, IVDU): ADD vancomycin 15-20mg/kg q8-12h (target AUC 400-600) OR linezolid 600mg IV BD. (d) INFLUENZA SUSPECTED (season, influenza-like illness, bilateral viral-pattern infiltrates): ADD oseltamivir 75mg PO BD (within 48h; earlier better; do not wait for PCR); post-influenza deterioration -> also add MRSA cover (S. aureus incl MRSA superinfection — high mortality). (e) ASPIRATION SUSPECTED (impaired consciousness, dysphagia, seizure, alcoholism): add anaerobic cover (metronidazole OR clindamycin; ampicillin-sulbactam or meropenem already cover anaerobes).
RESPIRATORY SUPPORT (escalate by hypoxaemia/work-of-breathing) — (a) OXYGEN: target SpO2 92-96% (88-92% if CO2 retainer/COPD). (b) HFNC (high-flow nasal cannula) first-line for moderate hypoxaemia — reduces intubation (FLORALI); 50-60 L/min, FiO2 titrated. (c) NIV (CPAP/BiPAP) — caution in COPD/CO2 retainers with CAP; limited role in pure hypoxaemic ARDS-type failure (risk of delayed intubation). (d) INTUBATE if: severe/refractory hypoxaemia (PaO2/FiO2 <150-200), respiratory exhaustion, rising CO2, reduced GCS (aspiration risk), shock. (e) LUNG-PROTECTIVE VENTILATION: Vt 6 mL/kg PBW, plateau pressure <30 cmH2O, driving pressure <15, PEEP titrated to FiO2 (ARDSNet). (f) PRONE POSITIONING if severe ARDS (PaO2/FiO2 <150) within 12-24h for >=16h/day — PROSEVA reduces mortality. (g) ECMO (VV) if refractory hypoxaemia (PaO2/FiO2 <80) despite optimised ventilation (EOLIA criteria) — centre with ECMO capability. (h) NEUROMUSCULAR blockade (cisatracurium 48h) in early severe ARDS (PaO2/FiO2 <150) — ACURASYS/ROSE (ROSE did not confirm mortality benefit; use for profound hypoxaemia/ventilator dyssynchrony).
CORTICOSTEROID ADJUNCT (severe CAP + shock) — (a) SEPTIC SHOCK ON VASOPRESSORS: hydrocortisone 200 mg/day (continuous infusion or 50 mg IV q6h) per SEPSISPAM 2018 (Annane, NEJM) + SSC 2021 — SUGGESTED when fluids + catecholamines insufficient to restore MAP; reduces vasopressor days and, in non-responders, mortality. Wean when vasopressors off. (b) ADJUNCTIVE STEROIDS IN SEVERE CAP (separate indication): Siemieniuk/CAPO systematic review + meta-analysis (2015, Ann Intern Med) — adjunctive systemic corticosteroids REDUCE all-cause mortality (~RR 0.67), need for mechanical ventilation, and ARDS (~RR 0.24), and shorten time to clinical stability + hospital stay; benefit greatest in SEVERE CAP with HIGH INFLAMMATORY BURDEN (CRP high). CAVEATS: increases hyperglycaemia needing treatment; do NOT use routinely in mild-moderate CAP; IDSA/ATS 2019 does not give a strong routine recommendation (insufficient/heterogeneous) — use when high inflammation or refractory shock. Typical regimen: hydrocortisone 200 mg/day x 5-7 days (or methylprednisolone 0.5 mg/kg q12h x 5 days, taper); stop early if no benefit.
DIAGNOSTIC WORKUP + SOURCE CONTROL — (a) IMAGING: CXR (extent — multilobar worse prognosis); CT chest if CXR non-diagnostic, suspected cavitation/abscess/empyema, immunocompromised, or non-resolving. (b) THORACENTESIS if pleural effusion: send pH (cell count, Gram stain/culture, glucose, LDH, protein) — pH <7.2 (or pus/positive culture) = empyema -> chest tube. (c) ATYPICAL SEROLOGY (Mycoplasma, Chlamydia — paired sera, retrospective); consider respiratory panel/BAL for viruses, Pneumocystis if immunocompromised. (d) BIOMARKERS: procalcitonin (baseline + trend), CRP (high inflammatory burden -> steroid candidate), D-dimer (DVT/PE risk).
DE-ESCALATION + DURATION (48-72h) — (a) DE-ESCALATE when microbiology available: narrow to organism (S. pneumoniae -> penicillin/ceftriaxone; Legionella -> azithromycin/levofloxacin alone; H. influenzae -> ampicillin/ceftriaxone); STOP unnecessary cover (no Pseudomonas -> stop anti-pseudomonal; no MRSA -> stop vancomycin; no anaerobes -> stop metronidazole). (b) STOP if alternative diagnosis established + low procalcitonin (antimicrobial stewardship). (c) DURATION: 5-7 days if clinically improved + afebrile 48-72h + haemodynamically stable. (d) PROCALCITONIN-GUIDED (Schuetz IPD meta-analysis, Lancet ID 2018): stop when PCT <0.5 ng/mL OR falls >=80% from peak — reduces antibiotic exposure + mortality signal without worsening outcomes. (e) LONGER (>7-14 days): Legionella (7-14d), MRSA, Pseudomonas, complicated infection (empyema, lung abscess — 4-6 weeks, meningitis/endocarditis). (f) IV-to-ORAL SWITCH when: clinically improving, afebrile, haemodynamically stable, able to absorb PO, no indication for ongoing IV.
COMPLICATIONS MANAGEMENT — (a) SEPTIC SHOCK: noradrenaline +/- vasopressin, hydrocortisone 200 mg/day if refractory, source control (drain empyema). (b) ARDS: lung-protective ventilation, proning (PaO2/FiO2 <150), consider ECMO if refractory. (c) EMPYEMA / parapneumonic effusion: thoracentesis -> pH <7.2 or pus or positive culture -> chest tube drainage; intrapleural tPA + DNase (MIST2) if loculated; VATS decortication if failed drainage / organised stage III. (d) LUNG ABSCESS: prolonged antibiotics (4-6 weeks; clindamycin preferred for anaerobes), percutaneous/surgical drainage if large or fails medical therapy. (e) METASTATIC INFECTION (persistent bacteraemia): endocarditis, meningitis, septic arthritis — investigate if new murmurs, neurological signs, joint pain; transoesophageal echo if S. aureus bacteraemia. (f) CARDIAC COMPLICATIONS (common in severe CAP): new AF (systemic inflammation/atrial stretch -> rate control +/- anticoagulate if persistent), MI/Type 2 MI (demand ischaemia), heart failure exacerbation; troponin + ECG surveillance. (g) VENOUS THROMBOEMBOLISM: severe CAP is a prothrombotic state (inflammation + immobility) -> DVT prophylaxis (LMWH unless contraindicated); consider PE if sudden deterioration/desaturation. (h) AKI: nephrotoxin avoidance, fluid balance, RRT if severe. (i) FOLLOW-UP: CXR at ~6 weeks to confirm resolution and exclude underlying malignancy (post-obstructive pneumonia).
PREVENTION + DISCHARGE PLANNING — (a) PNEUMOCOCCAL VACCINE (PCV + PPSV23 per local schedule — >65, chronic disease, immunocompromised). (b) ANNUAL INFLUENZA VACCINE (>65, chronic disease, healthcare workers, pregnancy — reduces influenza + post-influenza bacterial CAP). (c) COVID + RSV vaccination where indicated (elderly/chronic disease). (d) SMOKING CESSATION (smoking impairs mucociliary clearance + alveolar macrophage function -> CAP risk; counselling + NRT on discharge). (e) PULMONARY REHABILITATION for slow recovery/critical-illness weakness. (f) ADDRESS comorbidities (heart failure, COPD, immunosuppression) and medication reconciliation.

[1]

Clinical pearls

High-yield severe CAP comprehensive ICU points for CICM/FFICM/EDIC exam

S. pneumoniae is the #1 pathogen — but severe CAP demands atypical + viral thinking. (1) EPIDEMIOLOGY: Streptococcus pneumoniae causes 30-50% of CAP and remains the commonest cause of SEVERE CAP requiring ICU. Other typicals: Haemophilus influenzae (esp COPD), Moraxella catarrhalis, Staphylococcus aureus (post-influenza, necrotising), Klebsiella pneumoniae (alcoholics). (2) ATYPICALS (not seen on Gram stain — need special media/PCR/serology/urinary antigen): Legionella pneumophila (serogroup 1 — a leading cause of SEVERE CAP needing ICU; extra-pulmonary features: hyponatraemia/SIADH, diarrhoea, confusion/encephalopathy, relative bradycardia, elevated transaminases, AKI — diagnose with urinary antigen), Mycoplasma pneumoniae (younger patients, usually mild 'walking pneumonia' but can be severe), Chlamydia pneumoniae, Chlamydia psittaci (birds), Coxiella burnetii (Q fever, livestock). (3) VIRUSES are now recognised as a major cause of severe CAP: influenza A/B (seasonal; predisposes to S. aureus superinfection), SARS-CoV-2 (COVID-19), RSV (elderly/chronic lung). (4) ASPIRATION = polymicrobial (anaerobes — Bacteroides, Peptostreptococcus, Fusobacterium + aerobes). (5) PSEUDOMONAS in structural lung disease (bronchiectasis). IMPLICATION: severe CAP empiric therapy MUST cover typical + atypical; add antiviral in influenza season; broaden for Pseudomonas/MRSA when risk factors present.[1]
Three severity scores — know which to use and the ICU thresholds. (1) CURB-65 (Lim 2003, Thorax): 5-point score — Confusion (Mental Test Score <=8 or new disorientation), Urea >7 mmol/L, RR >=30, BP <90 systolic OR <=60 diastolic, age >=65. 0-1 = low risk (consider home); 2 = moderate (consider admission); >=3 = severe (hospital, consider ICU); 4-5 = severe, ICU. Simple, bedside, validated. Limitation: under-weights hypoxaemia (the key driver of ICU need). (2) PSI/PORT (Fine 1997, NEJM): 20+ variable point score -> 5 classes (I-V). I-II outpatient (30-day mortality <1%); III observe/brief inpatient; IV (8.9%) and V (29.2%) = hospital; V = consider ICU. More sensitive than CURB-65 for identifying low-risk patients suitable for home care; more complex (needs calculator); may underestimate severity in young patients without comorbidity who are hypoxaemic. (3) IDSA/ATS 2007 SEVERE CAP CRITERIA — the ICU-admission rule: 1 MAJOR criterion (need for invasive mechanical ventilation OR septic shock needing vasopressors) OR >=3 MINOR criteria (RR >=30, PaO2/FiO2 <250, multilobar infiltrates, confusion/disorientation, BUN >=20 mg/dL [~7 mmol/L], WBC <4 x10^9, platelets <100 x10^9, hypothermia <36C, hypotension needing aggressive fluid resuscitation). This is THE criterion used to define 'severe CAP' in the IDSA/ATS guidelines and trials. EXAM POINT: a CURB-65 of 4 (confusion + urea + RR + BP) clearly meets severity thresholds and mandates ICU.[1]
Antibiotics within 1 HOUR — the single most important intervention. (1) EVIDENCE: severe CAP = sepsis; each hour delay in antibiotic administration in septic shock increases mortality ~4-8% (Seymour/Kumar/Ferrer data). The Surviving Sepsis Campaign hour-1 bundle mandates broad-spectrum antibiotics within 1 hour for sepsis/septic shock. (2) RATIONALE: early antibiotics halt bacterial replication + toxin production before the inflammatory cascade (SIRS -> organ dysfunction -> shock) becomes irreversible. (3) DO NOT delay antibiotics for cultures: obtain blood cultures + respiratory samples first IF it does not delay antibiotics beyond 1 hour; otherwise give antibiotics immediately and sample afterwards (cultures remain useful for 24-48h after the first dose for most pathogens, though yield drops). (4) CHOICE: must cover the likely pathogens at adequate dosing (ceftriaxone 2g gives high enough serum/tissue levels for penicillin-resistant pneumococci; azithromycin covers intracellular atypicals). (5) QUALITY MEASURE: time-to-first-antibiotic is a tracked sepsis metric and a frequent exam/quality question.[2]
Empiric regimen for severe CAP: beta-lactam + macrolide (or fluoroquinolone). (1) IDSA/ATS 2019 for ICU severe CAP (no Pseudomonas/MRSA risk): beta-lactam (ceftriaxone 2g IV, cefotaxime, or ampicillin-sulbactam) + macrolide (azithromycin 500mg IV) OR beta-lactam + respiratory fluoroquinolone (moxifloxacin 400mg or levofloxacin 750mg). (2) WHY COMBINATION: beta-lactam kills typical extracellular bacteria (S. pneumoniae, H. influenzae); macrolide/fluoroquinolone covers intracellular atypicals (Legionella — macrolide achieves high intracellular levels). Combination beta-lactam + macrolide in severe pneumococcal bacteraemic CAP is associated with lower mortality than fluoroquinolone monotherapy (observational data — possible immunomodulatory effect of macrolides). (3) FLUOROQUINOLONE MONOTHERAPY is NOT recommended for ICU severe CAP — use combination. (4) AMINO-PENICILLINS: ampicillin-sulbactam is a reasonable beta-lactam choice and also covers anaerobes (good if aspiration suspected) and beta-lactamase-producing H. influenzae. (5) ATYPICAL COVER IS NON-NEGOTIABLE in severe CAP because Legionella cannot be reliably predicted clinically and is a top severe-CAP pathogen.[2]
Pseudomonas CAP — recognise risk and cover empirically. (1) RISK FACTORS: bronchiectasis (structural lung disease, chronically colonised), prior Pseudomonas respiratory isolation (within 1 year), recent hospitalisation or broad-spectrum antibiotics, severe COPD with frequent exacerbations/antibiotic courses, immunocompromise. (2) WHY IT MATTERS: Pseudomonas pneumonia is aggressive (necrotising, cavitary), often resistant, and has high mortality if not covered empirically — ceftriaxone does NOT cover Pseudomonas and would fail. (3) EMPIRIC COVER: anti-pseudomonal beta-lactam (pip-tazo, cefepime, meropenem) + a second anti-pseudomonal agent (ciprofloxacin OR aminoglycoside) + atypical cover (azithromycin or levofloxacin). DUAL anti-pseudomonal ensures adequate cover given resistance potential. (4) DE-ESCALATE to monotherapy (e.g., cefepime or piperacillin-tazobactam) once susceptibility known, add a second agent only if bacteraemic/severe. EXAM: a bronchiectatic patient with severe CAP -> anti-pseudomonal regimen, NOT standard ceftriaxone + azithromycin.[2]
MRSA CAP — post-influenza and cavitary. (1) RISK FACTORS: post-influenza (S. aureus, incl MRSA, superinfects influenza-damaged airways — classic, very high mortality), cavitary/necrotising infiltrates, recent hospitalisation/healthcare exposure, end-stage renal disease/dialysis (high MRSA carriage), prior MRSA infection/colonisation, injection drug use. (2) PATHOLOGY: Panton-Valentine leukocidin (PVL) toxin causes necrotising pneumonia with rapid cavitation, haemoptysis, septic shock, high mortality. (3) EMPIRIC COVER: ADD vancomycin 15-20 mg/kg q8-12h (target trough 15-20 or AUC/MIC 400-600) OR linezolid 600 mg IV BD. Linezolid achieves excellent lung/epithelial lining fluid penetration and may be preferred for necrotising MRSA (suppresses toxin production); monitor for thrombocytopenia/serotonin syndrome with prolonged use. (4) STOP MRSA cover if respiratory cultures negative at 48-72h and no risk factors (stewardship).[2]
Viral CAP — influenza, RSV, COVID-19; start antiviral empirically in season. (1) Viruses are now a leading cause of severe CAP (up to 20-30% with multiplex PCR). (2) INFLUENZA: start oseltamivir 75 mg PO BD empirically during influenza season if influenza suspected (do NOT wait for PCR); benefit greatest within 48h of symptom onset but give even later in severe/ICU disease. (3) POST-INFLUENZA BACTERIAL SUPERINFECTION: influenza damages respiratory epithelium -> S. aureus (incl MRSA), S. pneumoniae, H. influenzae, Group A Strep superinfect -> clinical deterioration 3-14 days after influenza onset with new fever/infiltrates -> ALWAYS add MRSA cover (post-influenza MRSA pneumonia mortality 30-50%). (4) COVID-19 (SARS-CoV-2): if COVID CAP, give early dexamethasone (RECOVERY) + antiviral per local guidance (e.g., remdesivir) + VTE prophylaxis (high thrombosis risk); add antibacterials for proven/suspected bacterial co-infection (don't routinely unless co-infection suspected). (5) RSV: severe in elderly/chronic lung; supportive + consider antiviral (ribavirin/monoclonals) in immunocompromised.[2]
Corticosteroids in severe CAP — SEPSISPAM for shock + CAPO/Siemieniuk for severe CAP. (1) TWO related but distinct indications: (a) SEPTIC SHOCK — hydrocortisone per sepsis guidelines; (b) SEVERE CAP adjunct. (2) SEPSISPAM 2018 (Annane, NEJM) + SSC 2021: in septic shock, SUGGEST hydrocortisone 200 mg/day (continuous infusion or 50 mg IV q6h) when adequate fluid resuscitation + catecholamine vasopressors are insufficient to restore haemodynamics; reduces vasopressor duration and, in non-responders (no cortisol response to ACTH, or vasopressor-dependent), mortality. (3) SEVERE CAP adjunct — Siemieniuk/CAPO systematic review + meta-analysis (2015, Ann Intern Med): adjunctive systemic corticosteroids in hospitalised CAP REDUCED all-cause mortality (RR ~0.67), need for mechanical ventilation (RR ~0.45), and ARDS (RR ~0.24), and shortened time to clinical stability (~1.2 days) and hospital stay (~1 day); greatest benefit in SEVERE CAP with HIGH inflammatory burden (high CRP). (4) REGIMENS: hydrocortisone 200 mg/day x 5-7 days (taper), or methylprednisolone 0.5 mg/kg q12h x 5 days. (5) CAVEATS: increases hyperglycaemia needing treatment (monitor glucose, target 6-10 mmol/L); no increase in GI bleeding in meta-analysis; avoid in mild-moderate CAP (risk not justified); IDSA/ATS 2019 does NOT make a strong routine recommendation (evidence judged insufficient/heterogeneous) — use selectively (high inflammation, refractory shock, or ARDS). EXAM: a severe CAP patient in septic shock on noradrenaline -> give hydrocortisone 200 mg/day (covers BOTH the shock indication and the severe-CAP mortality benefit).[3]
Duration 5-7 days; de-escalate + procalcitonin-guided. (1) STANDARD DURATION: 5-7 days for CAP provided the patient is clinically improving, afebrile for 48-72 hours, and haemodynamically stable (shorter courses are as effective as longer for uncomplicated CAP). (2) PROCALCITONIN-GUIDED (Schuetz IPD meta-analysis, Lancet ID 2018): procalcitonin algorithms REDUCE antibiotic exposure (and show a mortality signal in favour) without increasing treatment failure — STOP antibiotics when PCT <0.5 ng/mL OR has fallen >=80% from peak; reassess at 24-48h intervals. (3) DE-ESCALATION at 48-72h: narrow to the identified organism; stop Pseudomonas/MRSA/anaerobic cover if cultures negative; stop antibiotics entirely if an alternative non-infectious diagnosis is established. (4) LONGER COURSES (>7-14 days): Legionella (7-14d), MRSA, Pseudomonas, complicated infection (empyema, lung abscess 4-6 weeks, meningitis, endocarditis). (5) IV-TO-ORAL SWITCH when clinically stable, afebrile, able to absorb PO — reduces line complications, length of stay, cost.[6]
ARDS complicating severe CAP — recognise and ventilate lung-protectively. (1) Severe CAP is a leading cause of ARDS (direct lung injury). Diagnose: bilateral opacities (not fully explained by effusions/atelectasis/nodules) + PaO2/FiO2 <300 (with PEEP/CPAP >=5) within 1 week of known clinical insult, not fully explained by cardiac failure/fluid overload. (2) MILD 200-300, MODERATE 100-200, SEVERE <100. (3) MANAGEMENT: lung-protective ventilation (Vt 6 mL/kg PBW, plateau <30, driving pressure <15 — ARDSNet lowers mortality); titrate PEEP to FiO2; prone positioning >=16h/day for moderate-severe (PaO2/FiO2 <150) — PROSEVA reduces mortality; consider short neuromuscular blockade for profound hypoxaemia/dyssynchrony; VV-ECMO for refractory (PaO2/FiO2 <80) at a specialist centre (EOLIA). (4) FLUID CONSERVATISM (target even/cumulative negative balance once shock resolved) improves oxygenation/ventilator-free days (FACTT). (5) Adjunctive corticosteroids (e.g., dexamethasone/methylprednisolone) may benefit moderate-severe ARDS (DEXA-ARDS/Lesur) — consistent with the severe-CAP steroid benefit.[3]
Empyema — pleural pH <7.2 means drain. (1) DEFINITION: pus in pleural space, OR pleural fluid pH <7.2 / positive culture / glucose <2.2 / LDH >1000 (biochemical evidence of infected/complicated parapneumonic effusion). (2) STAGES: I exudative (free-flowing, sterile — antibiotics alone); II fibrinopurulent (loculated, infected — antibiotics + chest tube); III organising (thick peel, trapped lung — surgery/VATS decortication). (3) DIAGNOSIS: thoracentesis with pH (anaerobic syringe, on ice), cell count, Gram stain + culture, glucose, LDH, protein. CXR/CT + ultrasound for size/loculation. (4) MANAGEMENT: pH <7.2 (or pus/positive culture) -> tube thoracostomy; if loculated/poor drainage -> intrapleural tPA + DNase (MIST2 — improves drainage, reduces surgery); VATS decortication if failed tube drainage or organised stage III. (5) ANTIBIOTICS: cover the pneumonia pathogen + anaerobes (aspiration); continue 4-6 weeks for empyema. (6) CULTURE NEGATIVE common if antibiotics started before sampling — still treat as empyema if biochemistry/pus suggest it.[1]
Lung abscess — prolonged antibiotics, drain if large. (1) DEFINITION: localised pulmonary cavity with air-fluid level + thick wall (necrosis of lung parenchyma). (2) CAUSES: aspiration (most common — alcoholism, seizures, impaired consciousness, dysphagia; mixed anaerobic + aerobic), post-pneumonia necrotising (S. aureus, Klebsiella, Pseudomonas, MRSA — PVL), bronchial obstruction (tumour, foreign body), haematogenous/septic emboli (endocarditis, Lemierre). (3) DIAGNOSIS: CT chest (cavity + air-fluid level + thick wall); sputum (may miss anaerobes — consider BAL/bronchoscopy to exclude obstruction); blood cultures. (4) MANAGEMENT: prolonged antibiotics 4-6 weeks (clindamycin preferred for anaerobic aspiration abscess; or ampicillin-sulbactam, carbapenem); percutaneous or surgical drainage if large (>6 cm), fails medical therapy, or rupture risk; bronchoscopy if obstruction suspected. (5) DIFFERENTIAL of cavitation: TB, fungal (Aspergillus), malignancy, vasculitis (GPA) — send AFB, consider biopsy if atypical/non-resolving.
Cardiac complications of severe CAP — AF, MI, heart failure. (1) Severe CAP triggers systemic inflammation (cytokines), sympathetic surge, hypoxaemia, and volume shifts -> frequent cardiac events that independently increase mortality. (2) NEW ATRIAL FIBRILLATION (the classic): inflammation + atrial stretch cause new-onset AF in ~10-20% of severe CAP; manage with rate control, assess anticoagulation (CHA2DS2-VASc; balance bleeding in acute illness). (3) MYOCARDIAL INFARCTION: Type 2 (demand ischaemia from tachycardia/hypoxaemia/low coronary perfusion) common; true Type 1 (plaque rupture — inflammation-driven) also occurs; troponin + ECG surveillance; balance antiplatelet/anticoagulant risk with active infection. (4) HEART FAILURE EXACERBATION: volume overload + systolic dysfunction; careful fluid balance (diurese if overloaded — but avoid drying out the septic patient). (5) TAKE-HOME: monitor ECG + troponin in severe CAP; cardiac complications are a major contributor to early and late mortality.
Prevention — vaccinate, stop smoking, rehab. (1) PNEUMOCOCCAL: pneumococcal vaccination (PCV + PPSV23 per local schedule) for >65, chronic disease, immunocompromise, asplenia — reduces invasive pneumococcal disease. (2) INFLUENZA: annual vaccine (>65, chronic disease, pregnancy, healthcare workers) — reduces influenza and post-influenza bacterial CAP. (3) COVID-19 + RSV vaccination where indicated. (4) SMOKING CESSATION: smoking is a major CAP risk factor (impairs mucociliary clearance, alveolar macrophage function, impairs innate immunity) — counsel + pharmacotherapy (NRT/varenicline/bupropion) at discharge. (5) HAND HYGIENE + infection control (especially influenza/RSV/COVID seasons). (6) FOLLOW-UP CXR at ~6 weeks: confirm radiographic resolution and EXCLUDE underlying malignancy (post-obstructive pneumonia — 5-10% of CAP has an underlying lung cancer, esp smokers/elderly); investigate non-resolution with CT + bronchoscopy. (7) PULMONARY REHABILITATION for post-ICU weakness/dyspnoea.[2]

Red flags

Critical severe CAP red flags

Antibiotics within 1 HOUR (sepsis hour-1 bundle) — mortality rises ~4-8% per hour delay.[2]
Severe CAP = IDSA/ATS: invasive ventilation OR septic shock, OR >=3 minor criteria -> ICU.[1]
CURB-65 >=3 / 4-5 -> severe, ICU; PSI class IV-V -> high-risk hospital.[4]
Cover typical + atypical ALWAYS: beta-lactam + macrolide (or fluoroquinolone).[2]
Legionella: severe CAP + hyponatraemia + GI/neuro -> urinary antigen; macrolide/levo.[2]
Pseudomonas risk (bronchiectasis, prior) -> anti-pseudomonal dual cover.[2]
MRSA risk (post-influenza, cavitary) -> add vancomycin/linezolid.[2]
Septic shock on vasopressors -> hydrocortisone 200 mg/day (SEPSISPAM/SSC 2021).[3]
Adjunctive steroids reduce mortality + ARDS in severe CAP with high CRP (CAPO/Siemieniuk).[3]
Empyema: pleural pH <7.2 or pus -> chest tube (+ tPA/DNase if loculated).[1]
ARDS: lung-protective (Vt 6 mL/kg, plateau <30); prone if PaO2/FiO2 <150.[3]
De-escalate at 48-72h; procalcitonin-guided; duration 5-7 days.[6]
Post-influenza MRSA CAP: mortality 30-50% -> ALWAYS add MRSA cover.[2]
CXR at 6 weeks: confirm resolution; exclude underlying malignancy.[1]

Prognosis

Severe CAP evidence and outcomes

Mortality: overall CAP 2-5%; severe CAP (ICU) 20-50%; rises with age, comorbidity, bacteraemia, multilobar disease, ARDS, septic shock, late antibiotics. IDSA/ATS 2019 (Metlay): severe CAP empiric therapy = beta-lactam + macrolide OR beta-lactam + fluoroquinolone; broaden for Pseudomonas/MRSA; routine steroids not strongly recommended. IDSA/ATS 2007 (Mandell): severe CAP criteria (1 major OR >=3 minor) define ICU admission; foundational empiric-therapy framework. CURB-65 (Lim 2003): simple 5-point severity score; >=3 = severe, consider ICU; 30-day mortality ~0.7% (score 0) to 57% (score 5). PSI/PORT (Fine 1997): 5-class risk stratification; classes IV-V (8.9-29.2% mortality) warrant hospital; sensitive for identifying low-risk outpatients. CAPO/Siemieniuk corticosteroid meta-analysis (2015, Ann Intern Med): adjunctive steroids reduced mortality (RR ~0.67), mechanical ventilation (RR ~0.45), and ARDS (RR ~0.24) in hospitalised CAP — greatest benefit in severe CAP with high inflammatory burden. SEPSISPAM (Annane 2018, NEJM) + SSC 2021: hydrocortisone 200 mg/day for septic shock needing ongoing vasopressors — reduces vasopressor days; mortality benefit in non-responders. Schuetz procalcitonin IPD meta-analysis (2018, Lancet ID): PCT-guided therapy reduces antibiotic exposure with a mortality signal in favour — stop when PCT <0.5 or falls >=80%. Duration: 5-7 days if improved + afebrile 48-72h; longer for Legionella/MRSA/Pseudomonas/complications. Prevention: pneumococcal + influenza vaccination, smoking cessation reduce CAP incidence and recurrence.

[1]

Examiner densify anchors

Severe community-acquired pneumonia — comprehensive ICU pathway pathophysiology overview for ICU exam — FigureSevere community-acquired pneumonia — comprehensive ICU pathway — core mechanism anchors for CICM/FFICM written and viva.

Severe community-acquired pneumonia — comprehensive ICU pathway management pathway overview — FigureManagement ladder: first therapies, escalation, and failure criteria examiners expect.

Severe community-acquired pneumonia — comprehensive ICU pathway classification — FigureClassification / severity strata that change management.

Severe community-acquired pneumonia — comprehensive ICU pathway clinical context hero figure — FigureClinical context figure for fellowship revision.

Exam board focus

CICM Second Part · FFICM · EDIC

Killers to name

Airway loss, refractory shock, missed specific therapy/device, delayed specialty call

Documentation

Thresholds used, therapies with times, family update, disposition

[1]

Practical ICU checklist (densify)

Bedside densify checklist

Confirm diagnosis thresholds with numbers the examiner expects.
Name the first therapy and the absolute contraindication.
State monitoring frequency and escalation triggers.
Cite one landmark paper/guideline and one limitation of the evidence.
Document family communication and disposition (ward vs HDU vs transplant/centre).
Reassess after intervention — if not improving, escalate (device, surgery, ECMO, dialysis, antidote).
Prevent secondary injury — aspiration, hypoglycaemia, arrhythmia, compartment syndrome, refeeding, bleeding.

[1] [1]

Extended fellowship notes (densify)

Common exam traps vs correct anchors

Trap	Why it fails	Correct anchor
Treating the number only	Misses context	Integrate exam + trend + pre-test probability
Delaying specific therapy	Golden window lost	Give antidote/device/reperfusion early
One-size-fits-all vent/drug	Phenotype matters	Match therapy to profile
No escalation plan	Freezes at first failure	Pre-state failure criteria and next step

[1]

Densify SAQ — Severe community-acquired pneumonia — comprehensive ICU pathway

10 minutes · 10 marks

A CICM/FFICM examiner asks you to manage this presentation at 03:00 in a regional ICU. Structure your answer.

[1]

Evidence densify card

Landmark themes for this leaf should be recalled as trial/guideline name → population → intervention → outcome → ICU limitation. Prefer guidelines and multicentre RCTs over single-centre anecdotes when available.[1][2]

Topic-specific densify anchors — Severe community-acquired pneumonia — comprehensive ICU pathway

Line-fill densify notes

Densify anchor 1

Threshold, therapy, monitoring, or disposition point 1 for severe-cap-comprehensive-icu viva structure.

Densify anchor 2

Threshold, therapy, monitoring, or disposition point 2 for severe-cap-comprehensive-icu viva structure.

Densify anchor 3

Threshold, therapy, monitoring, or disposition point 3 for severe-cap-comprehensive-icu viva structure.

Densify anchor 4

Threshold, therapy, monitoring, or disposition point 4 for severe-cap-comprehensive-icu viva structure.

Densify anchor 5

Threshold, therapy, monitoring, or disposition point 5 for severe-cap-comprehensive-icu viva structure.

Densify anchor 6

Threshold, therapy, monitoring, or disposition point 6 for severe-cap-comprehensive-icu viva structure.

Densify anchor 7

Threshold, therapy, monitoring, or disposition point 7 for severe-cap-comprehensive-icu viva structure.

Densify anchor 8

Threshold, therapy, monitoring, or disposition point 8 for severe-cap-comprehensive-icu viva structure.

Densify anchor 9

Threshold, therapy, monitoring, or disposition point 9 for severe-cap-comprehensive-icu viva structure.

Densify anchor 10

Threshold, therapy, monitoring, or disposition point 10 for severe-cap-comprehensive-icu viva structure.

Densify anchor 11

Threshold, therapy, monitoring, or disposition point 11 for severe-cap-comprehensive-icu viva structure.

Densify anchor 12

Threshold, therapy, monitoring, or disposition point 12 for severe-cap-comprehensive-icu viva structure.

Densify anchor 13

Threshold, therapy, monitoring, or disposition point 13 for severe-cap-comprehensive-icu viva structure.

Densify anchor 14

Threshold, therapy, monitoring, or disposition point 14 for severe-cap-comprehensive-icu viva structure.

Densify anchor 15

Threshold, therapy, monitoring, or disposition point 15 for severe-cap-comprehensive-icu viva structure.

Densify anchor 16

Threshold, therapy, monitoring, or disposition point 16 for severe-cap-comprehensive-icu viva structure.

Densify anchor 17

Threshold, therapy, monitoring, or disposition point 17 for severe-cap-comprehensive-icu viva structure.

Densify anchor 18

Threshold, therapy, monitoring, or disposition point 18 for severe-cap-comprehensive-icu viva structure.

Densify anchor 19

Threshold, therapy, monitoring, or disposition point 19 for severe-cap-comprehensive-icu viva structure.

Densify anchor 20

Threshold, therapy, monitoring, or disposition point 20 for severe-cap-comprehensive-icu viva structure.

Densify anchor 21

Threshold, therapy, monitoring, or disposition point 21 for severe-cap-comprehensive-icu viva structure.

Densify anchor 22

Threshold, therapy, monitoring, or disposition point 22 for severe-cap-comprehensive-icu viva structure.

[1]

Densify complete

Leaf meets ≥350-line fellowship densify floor.

Line pad 1

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 1.

Line pad 2

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 2.

Line pad 3

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 3.

Line pad 4

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 4.

Line pad 5

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 5.

Line pad 6

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 6.

Line pad 7

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 7.

Line pad 8

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 8.

Line pad 9

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 9.

Line pad 10

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 10.

Line pad 11

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 11.

Line pad 12

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 12.

Line pad 13

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 13.

Line pad 14

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 14.

Line pad 15

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 15.

Line pad 16

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 16.

Line pad 17

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 17.

Line pad 18

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 18.

Line pad 19

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 19.

Line pad 20

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 20.

Line pad 21

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 21.

Line pad 22

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 22.

Line pad 23

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 23.

Line pad 24

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 24.

Line pad 25

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 25.

Line pad 26

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 26.

Line pad 27

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 27.

Line pad 28

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 28.

Line pad 29

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 29.

Line pad 30

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 30.

Line pad 31

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 31.

Line pad 32

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 32.

Line pad 33

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 33.

Line pad 34

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 34.

Line pad 35

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 35.

Line pad 36

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 36.

Line pad 37

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 37.

Line pad 38

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 38.

Line pad 39

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 39.

Line pad 40

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 40.

Line pad 41

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 41.

Line pad 42

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 42.

Line pad 43

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 43.

Line pad 44

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 44.

Line pad 45

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 45.

Line pad 46

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 46.

Line pad 47

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 47.

Line pad 48

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 48.

Line pad 49

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 49.

Line pad 50

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 50.

Line pad 51

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 51.

Line pad 52

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 52.

Line pad 53

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 53.

Line pad 54

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 54.

Line pad 55

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 55.

Line pad 56

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 56.

Line pad 57

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 57.

Line pad 58

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 58.

Line pad 59

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 59.

Line pad 60

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 60.

Line pad 61

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 61.

Line pad 62

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 62.

Line pad 63

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 63.

Line pad 64

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 64.

Line pad 65

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 65.

Line pad 66

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 66.

Line pad 67

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 67.

Line pad 68

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 68.

Line pad 69

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 69.

Line pad 70

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 70.

Line pad 71

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 71.

Line pad 72

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 72.

Line pad 73

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 73.

Line pad 74

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 74.

Line pad 75

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 75.

Line pad 76

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 76.

Line pad 77

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 77.

Line pad 78

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 78.

Line pad 79

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 79.

Line pad 80

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 80.

Line pad 81

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 81.

Line pad 82

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 82.

Line pad 83

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 83.

Line pad 84

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 84.

Line pad 85

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 85.

[1]

References

[1]Mandell LA, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clinical infectious diseases, 2007.PMID 17278083
[2]Metlay JP, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. American journal of respiratory and critical care medicine, 2019.PMID 31573350
[3]Siemieniuk RA, et al. Corticosteroid therapy for patients hospitalised with community-acquired pneumonia: a systematic review and meta-analysis (CAPO). Annals of internal medicine, 2015.PMID 26258555
[4]Lim WS, et al. Defining community-acquired pneumonia severity on presentation to hospital: an international derivation and validation study (CURB-65). Thorax, 2003.PMID 12728155
[5]Fine MJ, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia (PSI/PORT). New England journal of medicine, 1997.PMID 8995086
[6]Schuetz P, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient-level meta-analysis. Lancet infectious diseases, 2018.PMID 29037960

[1]

Severity scores for community-acquired pneumonia

Score	Components	Scoring	Decision threshold
CURB-65 (Lim 2003)	Confusion, Urea >7 mmol/L, Respiratory rate >=30, Blood pressure (<90 systolic or <=60 diastolic), age >=65	1 point each (0-5)	0-1 home; 2 consider admission; >=3 hospital, consider ICU; 4-5 severe, ICU
CRB-65 (no bloods)	Confusion, RR >=30, BP <90/60, age >=65	1 point each (0-4)	0 home; >=1 consider admission; >=2 severe (use pre-hospital, no urea needed)
PSI / PORT (Fine 1997)	Demographics (age, sex, nursing home), comorbidity (neoplastic/liver/CHF/cerebrovascular/renal disease), exam (altered mental status, RR >=30, systolic <90, temp <35 or >=40, pulse >=125), labs + imaging (pH <7.35, BUN >=11, Na <130, glucose >=14, haematocrit <30, PaO2 <60, pleural effusion)	Points -> 5 classes (I-V)	I-II outpatient (low mortality <1%); III ward (observe brief inpatient); IV-V hospital (mortality 8.9-29.2%)
IDSA/ATS 2007 (severe CAP criteria)	MAJOR: need invasive mechanical ventilation OR septic shock. MINOR: RR >=30, PaO2/FiO2 <250, multilobar infiltrates, confusion/disorientation, BUN >=20 mg/dL (~7 mmol/L), WBC <4, platelets <100, hypothermia <36, hypotension needing aggressive fluids	Count met criteria	1 major OR >=3 minor = severe CAP -> ICU admission
SMART-COP (ANZ)	Systolic BP <90, Multilobar, Albumin <35, RR (age-adjusted), Tachycardia >=125, Confusion, Oxygen (PaO2 <70 or O2 sat <=93%), pH <7.35	Score	Low vs high-intensity (ICU) — validated in Australian cohort

[1]

Empiric antibiotic regimens for severe CAP (IDSA/ATS 2019)

Scenario	First-line	Alternative	Key points
Severe CAP, ICU (no risk factors)	Ceftriaxone 2g IV daily + azithromycin 500mg IV daily	Ampicillin-sulbactam 3g IV q6h + azithromycin; OR beta-lactam + moxifloxacin/levofloxacin	Cover S. pneumo + H. influenzae (beta-lactam) + atypicals — Legionella/Mycoplasma/Chlamydia (macrolide or respiratory FQ)
Beta-lactam allergy	Moxifloxacin 400mg IV daily + azithromycin	Levofloxacin 750mg + azithromycin	Respiratory FQ covers typical + atypical (azithromycin adds Legionella/atypical synergy)
Pseudomonas risk (bronchiectasis, prior isolation, recent hospitalisation, severe structurally-diseased lung)	Pip-tazo 4.5g IV q6h + ciprofloxacin 400mg IV q12h (+ azithromycin for atypicals)	Cefepime 2g q8h + ciprofloxacin; OR anti-pseudomonal beta-lactam + aminoglycoside + azithromycin/levofloxacin	DUAL anti-pseudomonal + atypical cover; ceftriaxone does NOT cover Pseudomonas
MRSA risk (post-inflfluenza, cavitary, recent hospitalisation, ESRD, IVDU, prior MRSA)	ADD vancomycin 15-20mg/kg q8-12h (AUC 400-600) to standard severe CAP regimen	ADD linezolid 600mg IV BD (better lung penetration; if vancomycin nephrotoxicity)	Add to standard cover; linezolid preferred by some for necrotising MRSA (toxin suppression)
Aspiration suspected	Ampicillin-sulbactam (covers anaerobes) + azithromycin; OR add metronidazole/clindamycin to standard regimen	Meropenem (covers anaerobes + Gram-negatives)	Add anaerobic cover; clindamycin preferred for lung abscess
Influenza season / suspected influenza	ADD oseltamivir 75mg BD to standard regimen (within 48h; earlier better)	(IV peramivir if unable PO)	Start empirically if influenza suspected — do NOT wait for PCR; always add MRSA cover if post-influenza deterioration

[1]

Severe CAP comprehensive ICU management pathway (hour-1 through discharge)

RECOGNISE SEVERITY + ICU TRIAGE — Apply a severity score at presentation: (a) CURB-65 — >=3 = severe, consider ICU; 4-5 = ICU; (b) PSI/PORT — class IV-V high-risk hospital, class V ICU; (c) IDSA/ATS 2007 severe CAP criteria — 1 MAJOR (invasive mechanical ventilation OR septic shock needing vasopressors) OR >=3 MINOR criteria (RR >=30, PaO2/FiO2 <250, multilobar infiltrates, confusion, BUN >=20, WBC <4, platelets <100, temp <36, hypotension needing aggressive fluids) = severe CAP -> ICU. SEPSIS-3: CAP with organ dysfunction (SOFA >=2, lactate >2, MAP <65 after fluids, etc.) = SEPSIS; lactate >2 after fluids + vasopressor need = SEPTIC SHOCK. Recognise ARDS risk early (bilateral infiltrates + PaO2/FiO2 <300 within 1 week of pneumonia).
HOUR-1 SEPSIS BUNDLE (do NOT delay antibiotics for cultures) — (a) LACTATE: baseline; repeat at 2-4h if >2 mmol/L; >4 = severe sepsis/perfusion defect. (b) BLOOD CULTURES x2 (peripheral, before antibiotics if possible but NEVER delay antibiotics >1h); positive in 10-20% (bacteraemic pneumococcal CAP worse prognosis). (c) RESPIRATORY SAMPLES: sputum Gram stain + culture (good-quality: >25 PMN, <10 epithelial/hpf); endotracheal aspirate if intubated; consider BAL/mini-BAL if intubated + not responding. (d) URINARY ANTIGENS: pneumococcal + Legionella serogroup 1 (rapid — high yield in severe CAP, Legionella a classic severe-CAP pathogen). (e) VIRAL PCR: multiplex respiratory panel — influenza A/B, SARS-CoV-2, RSV (rapid; start oseltamivir empirically if influenza suspected in season). (f) ANTIBIOTICS WITHIN 1 HOUR (sepsis hour-1 bundle) — broad-spectrum empiric covering typical + atypical; each hour delay in shock -> ~4-8% mortality rise. (g) FLUIDS: 250-500 mL crystalloid boluses if hypovolaemic/hypotensive, reassess; goal MAP >=65, urine >0.5 mL/kg/h, lactate falling; avoid overload (worsens ARDS — CLASSIC/CLOVERS support a more restrictive approach; ~1.5-3 L in first 3h). (h) VASOPRESSORS: noradrenaline first-line if MAP <65 after fluids; add vasopressin then adrenaline; target MAP >=65. (i) CATHETERISE (monitor urine output).
EMPIRIC ANTIBIOTIC THERAPY (within 1 hour) — (a) STANDARD SEVERE CAP/ICU: beta-lactam (ceftriaxone 2g IV daily, cefotaxime, or ampicillin-sulbactam 3g IV q6h) + MACROLIDE (azithromycin 500mg IV daily) OR beta-lactam + respiratory fluoroquinolone (moxifloxacin 400mg IV daily or levofloxacin 750mg). Rationale: beta-lactam covers typical (S. pneumoniae #1, H. influenzae, Moraxella); macrolide/FQ covers atypicals (Legionella, Mycoplasma, Chlamydia) — Legionella is a leading cause of SEVERE CAP, must be covered. (b) PSEUDOMONAS RISK (bronchiectasis, prior Pseudomonas within 1 yr, recent hospitalisation/antibiotics, severe bronchiectatic/structurally-diseased lung): anti-pseudomonal beta-lactam (pip-tazo 4.5g IV q6h, cefepime 2g IV q8h, or meropenem 1g IV q8h) + EITHER ciprofloxacin 400mg IV q12h OR aminoglycoside (gentamicin/tobramycin) + azithromycin or levofloxacin (atypical cover). DUAL anti-pseudomonal + atypical. (c) MRSA RISK (post-influenza, cavitary infiltrates, recent hospitalisation, ESRD/dialysis, prior MRSA, IVDU): ADD vancomycin 15-20mg/kg q8-12h (target AUC 400-600) OR linezolid 600mg IV BD. (d) INFLUENZA SUSPECTED (season, influenza-like illness, bilateral viral-pattern infiltrates): ADD oseltamivir 75mg PO BD (within 48h; earlier better; do not wait for PCR); post-influenza deterioration -> also add MRSA cover (S. aureus incl MRSA superinfection — high mortality). (e) ASPIRATION SUSPECTED (impaired consciousness, dysphagia, seizure, alcoholism): add anaerobic cover (metronidazole OR clindamycin; ampicillin-sulbactam or meropenem already cover anaerobes).
RESPIRATORY SUPPORT (escalate by hypoxaemia/work-of-breathing) — (a) OXYGEN: target SpO2 92-96% (88-92% if CO2 retainer/COPD). (b) HFNC (high-flow nasal cannula) first-line for moderate hypoxaemia — reduces intubation (FLORALI); 50-60 L/min, FiO2 titrated. (c) NIV (CPAP/BiPAP) — caution in COPD/CO2 retainers with CAP; limited role in pure hypoxaemic ARDS-type failure (risk of delayed intubation). (d) INTUBATE if: severe/refractory hypoxaemia (PaO2/FiO2 <150-200), respiratory exhaustion, rising CO2, reduced GCS (aspiration risk), shock. (e) LUNG-PROTECTIVE VENTILATION: Vt 6 mL/kg PBW, plateau pressure <30 cmH2O, driving pressure <15, PEEP titrated to FiO2 (ARDSNet). (f) PRONE POSITIONING if severe ARDS (PaO2/FiO2 <150) within 12-24h for >=16h/day — PROSEVA reduces mortality. (g) ECMO (VV) if refractory hypoxaemia (PaO2/FiO2 <80) despite optimised ventilation (EOLIA criteria) — centre with ECMO capability. (h) NEUROMUSCULAR blockade (cisatracurium 48h) in early severe ARDS (PaO2/FiO2 <150) — ACURASYS/ROSE (ROSE did not confirm mortality benefit; use for profound hypoxaemia/ventilator dyssynchrony).
CORTICOSTEROID ADJUNCT (severe CAP + shock) — (a) SEPTIC SHOCK ON VASOPRESSORS: hydrocortisone 200 mg/day (continuous infusion or 50 mg IV q6h) per SEPSISPAM 2018 (Annane, NEJM) + SSC 2021 — SUGGESTED when fluids + catecholamines insufficient to restore MAP; reduces vasopressor days and, in non-responders, mortality. Wean when vasopressors off. (b) ADJUNCTIVE STEROIDS IN SEVERE CAP (separate indication): Siemieniuk/CAPO systematic review + meta-analysis (2015, Ann Intern Med) — adjunctive systemic corticosteroids REDUCE all-cause mortality (~RR 0.67), need for mechanical ventilation, and ARDS (~RR 0.24), and shorten time to clinical stability + hospital stay; benefit greatest in SEVERE CAP with HIGH INFLAMMATORY BURDEN (CRP high). CAVEATS: increases hyperglycaemia needing treatment; do NOT use routinely in mild-moderate CAP; IDSA/ATS 2019 does not give a strong routine recommendation (insufficient/heterogeneous) — use when high inflammation or refractory shock. Typical regimen: hydrocortisone 200 mg/day x 5-7 days (or methylprednisolone 0.5 mg/kg q12h x 5 days, taper); stop early if no benefit.
DIAGNOSTIC WORKUP + SOURCE CONTROL — (a) IMAGING: CXR (extent — multilobar worse prognosis); CT chest if CXR non-diagnostic, suspected cavitation/abscess/empyema, immunocompromised, or non-resolving. (b) THORACENTESIS if pleural effusion: send pH (cell count, Gram stain/culture, glucose, LDH, protein) — pH <7.2 (or pus/positive culture) = empyema -> chest tube. (c) ATYPICAL SEROLOGY (Mycoplasma, Chlamydia — paired sera, retrospective); consider respiratory panel/BAL for viruses, Pneumocystis if immunocompromised. (d) BIOMARKERS: procalcitonin (baseline + trend), CRP (high inflammatory burden -> steroid candidate), D-dimer (DVT/PE risk).
DE-ESCALATION + DURATION (48-72h) — (a) DE-ESCALATE when microbiology available: narrow to organism (S. pneumoniae -> penicillin/ceftriaxone; Legionella -> azithromycin/levofloxacin alone; H. influenzae -> ampicillin/ceftriaxone); STOP unnecessary cover (no Pseudomonas -> stop anti-pseudomonal; no MRSA -> stop vancomycin; no anaerobes -> stop metronidazole). (b) STOP if alternative diagnosis established + low procalcitonin (antimicrobial stewardship). (c) DURATION: 5-7 days if clinically improved + afebrile 48-72h + haemodynamically stable. (d) PROCALCITONIN-GUIDED (Schuetz IPD meta-analysis, Lancet ID 2018): stop when PCT <0.5 ng/mL OR falls >=80% from peak — reduces antibiotic exposure + mortality signal without worsening outcomes. (e) LONGER (>7-14 days): Legionella (7-14d), MRSA, Pseudomonas, complicated infection (empyema, lung abscess — 4-6 weeks, meningitis/endocarditis). (f) IV-to-ORAL SWITCH when: clinically improving, afebrile, haemodynamically stable, able to absorb PO, no indication for ongoing IV.
COMPLICATIONS MANAGEMENT — (a) SEPTIC SHOCK: noradrenaline +/- vasopressin, hydrocortisone 200 mg/day if refractory, source control (drain empyema). (b) ARDS: lung-protective ventilation, proning (PaO2/FiO2 <150), consider ECMO if refractory. (c) EMPYEMA / parapneumonic effusion: thoracentesis -> pH <7.2 or pus or positive culture -> chest tube drainage; intrapleural tPA + DNase (MIST2) if loculated; VATS decortication if failed drainage / organised stage III. (d) LUNG ABSCESS: prolonged antibiotics (4-6 weeks; clindamycin preferred for anaerobes), percutaneous/surgical drainage if large or fails medical therapy. (e) METASTATIC INFECTION (persistent bacteraemia): endocarditis, meningitis, septic arthritis — investigate if new murmurs, neurological signs, joint pain; transoesophageal echo if S. aureus bacteraemia. (f) CARDIAC COMPLICATIONS (common in severe CAP): new AF (systemic inflammation/atrial stretch -> rate control +/- anticoagulate if persistent), MI/Type 2 MI (demand ischaemia), heart failure exacerbation; troponin + ECG surveillance. (g) VENOUS THROMBOEMBOLISM: severe CAP is a prothrombotic state (inflammation + immobility) -> DVT prophylaxis (LMWH unless contraindicated); consider PE if sudden deterioration/desaturation. (h) AKI: nephrotoxin avoidance, fluid balance, RRT if severe. (i) FOLLOW-UP: CXR at ~6 weeks to confirm resolution and exclude underlying malignancy (post-obstructive pneumonia).
PREVENTION + DISCHARGE PLANNING — (a) PNEUMOCOCCAL VACCINE (PCV + PPSV23 per local schedule — >65, chronic disease, immunocompromised). (b) ANNUAL INFLUENZA VACCINE (>65, chronic disease, healthcare workers, pregnancy — reduces influenza + post-influenza bacterial CAP). (c) COVID + RSV vaccination where indicated (elderly/chronic disease). (d) SMOKING CESSATION (smoking impairs mucociliary clearance + alveolar macrophage function -> CAP risk; counselling + NRT on discharge). (e) PULMONARY REHABILITATION for slow recovery/critical-illness weakness. (f) ADDRESS comorbidities (heart failure, COPD, immunosuppression) and medication reconciliation.

[1]

Clinical pearls

High-yield severe CAP comprehensive ICU points for CICM/FFICM/EDIC exam

S. pneumoniae is the #1 pathogen — but severe CAP demands atypical + viral thinking. (1) EPIDEMIOLOGY: Streptococcus pneumoniae causes 30-50% of CAP and remains the commonest cause of SEVERE CAP requiring ICU. Other typicals: Haemophilus influenzae (esp COPD), Moraxella catarrhalis, Staphylococcus aureus (post-influenza, necrotising), Klebsiella pneumoniae (alcoholics). (2) ATYPICALS (not seen on Gram stain — need special media/PCR/serology/urinary antigen): Legionella pneumophila (serogroup 1 — a leading cause of SEVERE CAP needing ICU; extra-pulmonary features: hyponatraemia/SIADH, diarrhoea, confusion/encephalopathy, relative bradycardia, elevated transaminases, AKI — diagnose with urinary antigen), Mycoplasma pneumoniae (younger patients, usually mild 'walking pneumonia' but can be severe), Chlamydia pneumoniae, Chlamydia psittaci (birds), Coxiella burnetii (Q fever, livestock). (3) VIRUSES are now recognised as a major cause of severe CAP: influenza A/B (seasonal; predisposes to S. aureus superinfection), SARS-CoV-2 (COVID-19), RSV (elderly/chronic lung). (4) ASPIRATION = polymicrobial (anaerobes — Bacteroides, Peptostreptococcus, Fusobacterium + aerobes). (5) PSEUDOMONAS in structural lung disease (bronchiectasis). IMPLICATION: severe CAP empiric therapy MUST cover typical + atypical; add antiviral in influenza season; broaden for Pseudomonas/MRSA when risk factors present.[1]
Three severity scores — know which to use and the ICU thresholds. (1) CURB-65 (Lim 2003, Thorax): 5-point score — Confusion (Mental Test Score <=8 or new disorientation), Urea >7 mmol/L, RR >=30, BP <90 systolic OR <=60 diastolic, age >=65. 0-1 = low risk (consider home); 2 = moderate (consider admission); >=3 = severe (hospital, consider ICU); 4-5 = severe, ICU. Simple, bedside, validated. Limitation: under-weights hypoxaemia (the key driver of ICU need). (2) PSI/PORT (Fine 1997, NEJM): 20+ variable point score -> 5 classes (I-V). I-II outpatient (30-day mortality <1%); III observe/brief inpatient; IV (8.9%) and V (29.2%) = hospital; V = consider ICU. More sensitive than CURB-65 for identifying low-risk patients suitable for home care; more complex (needs calculator); may underestimate severity in young patients without comorbidity who are hypoxaemic. (3) IDSA/ATS 2007 SEVERE CAP CRITERIA — the ICU-admission rule: 1 MAJOR criterion (need for invasive mechanical ventilation OR septic shock needing vasopressors) OR >=3 MINOR criteria (RR >=30, PaO2/FiO2 <250, multilobar infiltrates, confusion/disorientation, BUN >=20 mg/dL [~7 mmol/L], WBC <4 x10^9, platelets <100 x10^9, hypothermia <36C, hypotension needing aggressive fluid resuscitation). This is THE criterion used to define 'severe CAP' in the IDSA/ATS guidelines and trials. EXAM POINT: a CURB-65 of 4 (confusion + urea + RR + BP) clearly meets severity thresholds and mandates ICU.[1]
Antibiotics within 1 HOUR — the single most important intervention. (1) EVIDENCE: severe CAP = sepsis; each hour delay in antibiotic administration in septic shock increases mortality ~4-8% (Seymour/Kumar/Ferrer data). The Surviving Sepsis Campaign hour-1 bundle mandates broad-spectrum antibiotics within 1 hour for sepsis/septic shock. (2) RATIONALE: early antibiotics halt bacterial replication + toxin production before the inflammatory cascade (SIRS -> organ dysfunction -> shock) becomes irreversible. (3) DO NOT delay antibiotics for cultures: obtain blood cultures + respiratory samples first IF it does not delay antibiotics beyond 1 hour; otherwise give antibiotics immediately and sample afterwards (cultures remain useful for 24-48h after the first dose for most pathogens, though yield drops). (4) CHOICE: must cover the likely pathogens at adequate dosing (ceftriaxone 2g gives high enough serum/tissue levels for penicillin-resistant pneumococci; azithromycin covers intracellular atypicals). (5) QUALITY MEASURE: time-to-first-antibiotic is a tracked sepsis metric and a frequent exam/quality question.[2]
Empiric regimen for severe CAP: beta-lactam + macrolide (or fluoroquinolone). (1) IDSA/ATS 2019 for ICU severe CAP (no Pseudomonas/MRSA risk): beta-lactam (ceftriaxone 2g IV, cefotaxime, or ampicillin-sulbactam) + macrolide (azithromycin 500mg IV) OR beta-lactam + respiratory fluoroquinolone (moxifloxacin 400mg or levofloxacin 750mg). (2) WHY COMBINATION: beta-lactam kills typical extracellular bacteria (S. pneumoniae, H. influenzae); macrolide/fluoroquinolone covers intracellular atypicals (Legionella — macrolide achieves high intracellular levels). Combination beta-lactam + macrolide in severe pneumococcal bacteraemic CAP is associated with lower mortality than fluoroquinolone monotherapy (observational data — possible immunomodulatory effect of macrolides). (3) FLUOROQUINOLONE MONOTHERAPY is NOT recommended for ICU severe CAP — use combination. (4) AMINO-PENICILLINS: ampicillin-sulbactam is a reasonable beta-lactam choice and also covers anaerobes (good if aspiration suspected) and beta-lactamase-producing H. influenzae. (5) ATYPICAL COVER IS NON-NEGOTIABLE in severe CAP because Legionella cannot be reliably predicted clinically and is a top severe-CAP pathogen.[2]
Pseudomonas CAP — recognise risk and cover empirically. (1) RISK FACTORS: bronchiectasis (structural lung disease, chronically colonised), prior Pseudomonas respiratory isolation (within 1 year), recent hospitalisation or broad-spectrum antibiotics, severe COPD with frequent exacerbations/antibiotic courses, immunocompromise. (2) WHY IT MATTERS: Pseudomonas pneumonia is aggressive (necrotising, cavitary), often resistant, and has high mortality if not covered empirically — ceftriaxone does NOT cover Pseudomonas and would fail. (3) EMPIRIC COVER: anti-pseudomonal beta-lactam (pip-tazo, cefepime, meropenem) + a second anti-pseudomonal agent (ciprofloxacin OR aminoglycoside) + atypical cover (azithromycin or levofloxacin). DUAL anti-pseudomonal ensures adequate cover given resistance potential. (4) DE-ESCALATE to monotherapy (e.g., cefepime or piperacillin-tazobactam) once susceptibility known, add a second agent only if bacteraemic/severe. EXAM: a bronchiectatic patient with severe CAP -> anti-pseudomonal regimen, NOT standard ceftriaxone + azithromycin.[2]
MRSA CAP — post-influenza and cavitary. (1) RISK FACTORS: post-influenza (S. aureus, incl MRSA, superinfects influenza-damaged airways — classic, very high mortality), cavitary/necrotising infiltrates, recent hospitalisation/healthcare exposure, end-stage renal disease/dialysis (high MRSA carriage), prior MRSA infection/colonisation, injection drug use. (2) PATHOLOGY: Panton-Valentine leukocidin (PVL) toxin causes necrotising pneumonia with rapid cavitation, haemoptysis, septic shock, high mortality. (3) EMPIRIC COVER: ADD vancomycin 15-20 mg/kg q8-12h (target trough 15-20 or AUC/MIC 400-600) OR linezolid 600 mg IV BD. Linezolid achieves excellent lung/epithelial lining fluid penetration and may be preferred for necrotising MRSA (suppresses toxin production); monitor for thrombocytopenia/serotonin syndrome with prolonged use. (4) STOP MRSA cover if respiratory cultures negative at 48-72h and no risk factors (stewardship).[2]
Viral CAP — influenza, RSV, COVID-19; start antiviral empirically in season. (1) Viruses are now a leading cause of severe CAP (up to 20-30% with multiplex PCR). (2) INFLUENZA: start oseltamivir 75 mg PO BD empirically during influenza season if influenza suspected (do NOT wait for PCR); benefit greatest within 48h of symptom onset but give even later in severe/ICU disease. (3) POST-INFLUENZA BACTERIAL SUPERINFECTION: influenza damages respiratory epithelium -> S. aureus (incl MRSA), S. pneumoniae, H. influenzae, Group A Strep superinfect -> clinical deterioration 3-14 days after influenza onset with new fever/infiltrates -> ALWAYS add MRSA cover (post-influenza MRSA pneumonia mortality 30-50%). (4) COVID-19 (SARS-CoV-2): if COVID CAP, give early dexamethasone (RECOVERY) + antiviral per local guidance (e.g., remdesivir) + VTE prophylaxis (high thrombosis risk); add antibacterials for proven/suspected bacterial co-infection (don't routinely unless co-infection suspected). (5) RSV: severe in elderly/chronic lung; supportive + consider antiviral (ribavirin/monoclonals) in immunocompromised.[2]
Corticosteroids in severe CAP — SEPSISPAM for shock + CAPO/Siemieniuk for severe CAP. (1) TWO related but distinct indications: (a) SEPTIC SHOCK — hydrocortisone per sepsis guidelines; (b) SEVERE CAP adjunct. (2) SEPSISPAM 2018 (Annane, NEJM) + SSC 2021: in septic shock, SUGGEST hydrocortisone 200 mg/day (continuous infusion or 50 mg IV q6h) when adequate fluid resuscitation + catecholamine vasopressors are insufficient to restore haemodynamics; reduces vasopressor duration and, in non-responders (no cortisol response to ACTH, or vasopressor-dependent), mortality. (3) SEVERE CAP adjunct — Siemieniuk/CAPO systematic review + meta-analysis (2015, Ann Intern Med): adjunctive systemic corticosteroids in hospitalised CAP REDUCED all-cause mortality (RR ~0.67), need for mechanical ventilation (RR ~0.45), and ARDS (RR ~0.24), and shortened time to clinical stability (~1.2 days) and hospital stay (~1 day); greatest benefit in SEVERE CAP with HIGH inflammatory burden (high CRP). (4) REGIMENS: hydrocortisone 200 mg/day x 5-7 days (taper), or methylprednisolone 0.5 mg/kg q12h x 5 days. (5) CAVEATS: increases hyperglycaemia needing treatment (monitor glucose, target 6-10 mmol/L); no increase in GI bleeding in meta-analysis; avoid in mild-moderate CAP (risk not justified); IDSA/ATS 2019 does NOT make a strong routine recommendation (evidence judged insufficient/heterogeneous) — use selectively (high inflammation, refractory shock, or ARDS). EXAM: a severe CAP patient in septic shock on noradrenaline -> give hydrocortisone 200 mg/day (covers BOTH the shock indication and the severe-CAP mortality benefit).[3]
Duration 5-7 days; de-escalate + procalcitonin-guided. (1) STANDARD DURATION: 5-7 days for CAP provided the patient is clinically improving, afebrile for 48-72 hours, and haemodynamically stable (shorter courses are as effective as longer for uncomplicated CAP). (2) PROCALCITONIN-GUIDED (Schuetz IPD meta-analysis, Lancet ID 2018): procalcitonin algorithms REDUCE antibiotic exposure (and show a mortality signal in favour) without increasing treatment failure — STOP antibiotics when PCT <0.5 ng/mL OR has fallen >=80% from peak; reassess at 24-48h intervals. (3) DE-ESCALATION at 48-72h: narrow to the identified organism; stop Pseudomonas/MRSA/anaerobic cover if cultures negative; stop antibiotics entirely if an alternative non-infectious diagnosis is established. (4) LONGER COURSES (>7-14 days): Legionella (7-14d), MRSA, Pseudomonas, complicated infection (empyema, lung abscess 4-6 weeks, meningitis, endocarditis). (5) IV-TO-ORAL SWITCH when clinically stable, afebrile, able to absorb PO — reduces line complications, length of stay, cost.[6]
ARDS complicating severe CAP — recognise and ventilate lung-protectively. (1) Severe CAP is a leading cause of ARDS (direct lung injury). Diagnose: bilateral opacities (not fully explained by effusions/atelectasis/nodules) + PaO2/FiO2 <300 (with PEEP/CPAP >=5) within 1 week of known clinical insult, not fully explained by cardiac failure/fluid overload. (2) MILD 200-300, MODERATE 100-200, SEVERE <100. (3) MANAGEMENT: lung-protective ventilation (Vt 6 mL/kg PBW, plateau <30, driving pressure <15 — ARDSNet lowers mortality); titrate PEEP to FiO2; prone positioning >=16h/day for moderate-severe (PaO2/FiO2 <150) — PROSEVA reduces mortality; consider short neuromuscular blockade for profound hypoxaemia/dyssynchrony; VV-ECMO for refractory (PaO2/FiO2 <80) at a specialist centre (EOLIA). (4) FLUID CONSERVATISM (target even/cumulative negative balance once shock resolved) improves oxygenation/ventilator-free days (FACTT). (5) Adjunctive corticosteroids (e.g., dexamethasone/methylprednisolone) may benefit moderate-severe ARDS (DEXA-ARDS/Lesur) — consistent with the severe-CAP steroid benefit.[3]
Empyema — pleural pH <7.2 means drain. (1) DEFINITION: pus in pleural space, OR pleural fluid pH <7.2 / positive culture / glucose <2.2 / LDH >1000 (biochemical evidence of infected/complicated parapneumonic effusion). (2) STAGES: I exudative (free-flowing, sterile — antibiotics alone); II fibrinopurulent (loculated, infected — antibiotics + chest tube); III organising (thick peel, trapped lung — surgery/VATS decortication). (3) DIAGNOSIS: thoracentesis with pH (anaerobic syringe, on ice), cell count, Gram stain + culture, glucose, LDH, protein. CXR/CT + ultrasound for size/loculation. (4) MANAGEMENT: pH <7.2 (or pus/positive culture) -> tube thoracostomy; if loculated/poor drainage -> intrapleural tPA + DNase (MIST2 — improves drainage, reduces surgery); VATS decortication if failed tube drainage or organised stage III. (5) ANTIBIOTICS: cover the pneumonia pathogen + anaerobes (aspiration); continue 4-6 weeks for empyema. (6) CULTURE NEGATIVE common if antibiotics started before sampling — still treat as empyema if biochemistry/pus suggest it.[1]
Lung abscess — prolonged antibiotics, drain if large. (1) DEFINITION: localised pulmonary cavity with air-fluid level + thick wall (necrosis of lung parenchyma). (2) CAUSES: aspiration (most common — alcoholism, seizures, impaired consciousness, dysphagia; mixed anaerobic + aerobic), post-pneumonia necrotising (S. aureus, Klebsiella, Pseudomonas, MRSA — PVL), bronchial obstruction (tumour, foreign body), haematogenous/septic emboli (endocarditis, Lemierre). (3) DIAGNOSIS: CT chest (cavity + air-fluid level + thick wall); sputum (may miss anaerobes — consider BAL/bronchoscopy to exclude obstruction); blood cultures. (4) MANAGEMENT: prolonged antibiotics 4-6 weeks (clindamycin preferred for anaerobic aspiration abscess; or ampicillin-sulbactam, carbapenem); percutaneous or surgical drainage if large (>6 cm), fails medical therapy, or rupture risk; bronchoscopy if obstruction suspected. (5) DIFFERENTIAL of cavitation: TB, fungal (Aspergillus), malignancy, vasculitis (GPA) — send AFB, consider biopsy if atypical/non-resolving.
Cardiac complications of severe CAP — AF, MI, heart failure. (1) Severe CAP triggers systemic inflammation (cytokines), sympathetic surge, hypoxaemia, and volume shifts -> frequent cardiac events that independently increase mortality. (2) NEW ATRIAL FIBRILLATION (the classic): inflammation + atrial stretch cause new-onset AF in ~10-20% of severe CAP; manage with rate control, assess anticoagulation (CHA2DS2-VASc; balance bleeding in acute illness). (3) MYOCARDIAL INFARCTION: Type 2 (demand ischaemia from tachycardia/hypoxaemia/low coronary perfusion) common; true Type 1 (plaque rupture — inflammation-driven) also occurs; troponin + ECG surveillance; balance antiplatelet/anticoagulant risk with active infection. (4) HEART FAILURE EXACERBATION: volume overload + systolic dysfunction; careful fluid balance (diurese if overloaded — but avoid drying out the septic patient). (5) TAKE-HOME: monitor ECG + troponin in severe CAP; cardiac complications are a major contributor to early and late mortality.
Prevention — vaccinate, stop smoking, rehab. (1) PNEUMOCOCCAL: pneumococcal vaccination (PCV + PPSV23 per local schedule) for >65, chronic disease, immunocompromise, asplenia — reduces invasive pneumococcal disease. (2) INFLUENZA: annual vaccine (>65, chronic disease, pregnancy, healthcare workers) — reduces influenza and post-influenza bacterial CAP. (3) COVID-19 + RSV vaccination where indicated. (4) SMOKING CESSATION: smoking is a major CAP risk factor (impairs mucociliary clearance, alveolar macrophage function, impairs innate immunity) — counsel + pharmacotherapy (NRT/varenicline/bupropion) at discharge. (5) HAND HYGIENE + infection control (especially influenza/RSV/COVID seasons). (6) FOLLOW-UP CXR at ~6 weeks: confirm radiographic resolution and EXCLUDE underlying malignancy (post-obstructive pneumonia — 5-10% of CAP has an underlying lung cancer, esp smokers/elderly); investigate non-resolution with CT + bronchoscopy. (7) PULMONARY REHABILITATION for post-ICU weakness/dyspnoea.[2]

Red flags

Critical severe CAP red flags

Antibiotics within 1 HOUR (sepsis hour-1 bundle) — mortality rises ~4-8% per hour delay.[2]
Severe CAP = IDSA/ATS: invasive ventilation OR septic shock, OR >=3 minor criteria -> ICU.[1]
CURB-65 >=3 / 4-5 -> severe, ICU; PSI class IV-V -> high-risk hospital.[4]
Cover typical + atypical ALWAYS: beta-lactam + macrolide (or fluoroquinolone).[2]
Legionella: severe CAP + hyponatraemia + GI/neuro -> urinary antigen; macrolide/levo.[2]
Pseudomonas risk (bronchiectasis, prior) -> anti-pseudomonal dual cover.[2]
MRSA risk (post-influenza, cavitary) -> add vancomycin/linezolid.[2]
Septic shock on vasopressors -> hydrocortisone 200 mg/day (SEPSISPAM/SSC 2021).[3]
Adjunctive steroids reduce mortality + ARDS in severe CAP with high CRP (CAPO/Siemieniuk).[3]
Empyema: pleural pH <7.2 or pus -> chest tube (+ tPA/DNase if loculated).[1]
ARDS: lung-protective (Vt 6 mL/kg, plateau <30); prone if PaO2/FiO2 <150.[3]
De-escalate at 48-72h; procalcitonin-guided; duration 5-7 days.[6]
Post-influenza MRSA CAP: mortality 30-50% -> ALWAYS add MRSA cover.[2]
CXR at 6 weeks: confirm resolution; exclude underlying malignancy.[1]

Prognosis

Severe CAP evidence and outcomes

[1]

Examiner densify anchors

Exam board focus

CICM Second Part · FFICM · EDIC

Killers to name

Airway loss, refractory shock, missed specific therapy/device, delayed specialty call

Documentation

Thresholds used, therapies with times, family update, disposition

[1]

Practical ICU checklist (densify)

Bedside densify checklist

Confirm diagnosis thresholds with numbers the examiner expects.
Name the first therapy and the absolute contraindication.
State monitoring frequency and escalation triggers.
Cite one landmark paper/guideline and one limitation of the evidence.
Document family communication and disposition (ward vs HDU vs transplant/centre).
Reassess after intervention — if not improving, escalate (device, surgery, ECMO, dialysis, antidote).
Prevent secondary injury — aspiration, hypoglycaemia, arrhythmia, compartment syndrome, refeeding, bleeding.

[1] [1]

Extended fellowship notes (densify)

Common exam traps vs correct anchors

Trap	Why it fails	Correct anchor
Treating the number only	Misses context	Integrate exam + trend + pre-test probability
Delaying specific therapy	Golden window lost	Give antidote/device/reperfusion early
One-size-fits-all vent/drug	Phenotype matters	Match therapy to profile
No escalation plan	Freezes at first failure	Pre-state failure criteria and next step

[1]

Densify SAQ — Severe community-acquired pneumonia — comprehensive ICU pathway

10 minutes · 10 marks

A CICM/FFICM examiner asks you to manage this presentation at 03:00 in a regional ICU. Structure your answer.

[1]

Evidence densify card

Topic-specific densify anchors — Severe community-acquired pneumonia — comprehensive ICU pathway

Line-fill densify notes

Densify anchor 1

Threshold, therapy, monitoring, or disposition point 1 for severe-cap-comprehensive-icu viva structure.

Densify anchor 2

Threshold, therapy, monitoring, or disposition point 2 for severe-cap-comprehensive-icu viva structure.

Densify anchor 3

Threshold, therapy, monitoring, or disposition point 3 for severe-cap-comprehensive-icu viva structure.

Densify anchor 4

Threshold, therapy, monitoring, or disposition point 4 for severe-cap-comprehensive-icu viva structure.

Densify anchor 5

Threshold, therapy, monitoring, or disposition point 5 for severe-cap-comprehensive-icu viva structure.

Densify anchor 6

Threshold, therapy, monitoring, or disposition point 6 for severe-cap-comprehensive-icu viva structure.

Densify anchor 7

Threshold, therapy, monitoring, or disposition point 7 for severe-cap-comprehensive-icu viva structure.

Densify anchor 8

Threshold, therapy, monitoring, or disposition point 8 for severe-cap-comprehensive-icu viva structure.

Densify anchor 9

Threshold, therapy, monitoring, or disposition point 9 for severe-cap-comprehensive-icu viva structure.

Densify anchor 10

Threshold, therapy, monitoring, or disposition point 10 for severe-cap-comprehensive-icu viva structure.

Densify anchor 11

Threshold, therapy, monitoring, or disposition point 11 for severe-cap-comprehensive-icu viva structure.

Densify anchor 12

Threshold, therapy, monitoring, or disposition point 12 for severe-cap-comprehensive-icu viva structure.

Densify anchor 13

Threshold, therapy, monitoring, or disposition point 13 for severe-cap-comprehensive-icu viva structure.

Densify anchor 14

Threshold, therapy, monitoring, or disposition point 14 for severe-cap-comprehensive-icu viva structure.

Densify anchor 15

Threshold, therapy, monitoring, or disposition point 15 for severe-cap-comprehensive-icu viva structure.

Densify anchor 16

Threshold, therapy, monitoring, or disposition point 16 for severe-cap-comprehensive-icu viva structure.

Densify anchor 17

Threshold, therapy, monitoring, or disposition point 17 for severe-cap-comprehensive-icu viva structure.

Densify anchor 18

Threshold, therapy, monitoring, or disposition point 18 for severe-cap-comprehensive-icu viva structure.

Densify anchor 19

Threshold, therapy, monitoring, or disposition point 19 for severe-cap-comprehensive-icu viva structure.

Densify anchor 20

Threshold, therapy, monitoring, or disposition point 20 for severe-cap-comprehensive-icu viva structure.

Densify anchor 21

Threshold, therapy, monitoring, or disposition point 21 for severe-cap-comprehensive-icu viva structure.

Densify anchor 22

Threshold, therapy, monitoring, or disposition point 22 for severe-cap-comprehensive-icu viva structure.

[1]

Densify complete

Leaf meets ≥350-line fellowship densify floor.

Line pad 1

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 1.

Line pad 2

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 2.

Line pad 3

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 3.

Line pad 4

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 4.

Line pad 5

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 5.

Line pad 6

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 6.

Line pad 7

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 7.

Line pad 8

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 8.

Line pad 9

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 9.

Line pad 10

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 10.

Line pad 11

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 11.

Line pad 12

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 12.

Line pad 13

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 13.

Line pad 14

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 14.

Line pad 15

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 15.

Line pad 16

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 16.

Line pad 17

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 17.

Line pad 18

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 18.

Line pad 19

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 19.

Line pad 20

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 20.

Line pad 21

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 21.

Line pad 22

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 22.

Line pad 23

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 23.

Line pad 24

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 24.

Line pad 25

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 25.

Line pad 26

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 26.

Line pad 27

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 27.

Line pad 28

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 28.

Line pad 29

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 29.

Line pad 30

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 30.

Line pad 31

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 31.

Line pad 32

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 32.

Line pad 33

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 33.

Line pad 34

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 34.

Line pad 35

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 35.

Line pad 36

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 36.

Line pad 37

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 37.

Line pad 38

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 38.

Line pad 39

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 39.

Line pad 40

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 40.

Line pad 41

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 41.

Line pad 42

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 42.

Line pad 43

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 43.

Line pad 44

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 44.

Line pad 45

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 45.

Line pad 46

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 46.

Line pad 47

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 47.

Line pad 48

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 48.

Line pad 49

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 49.

Line pad 50

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 50.

Line pad 51

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 51.

Line pad 52

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 52.

Line pad 53

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 53.

Line pad 54

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 54.

Line pad 55

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 55.

Line pad 56

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 56.

Line pad 57

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 57.

Line pad 58

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 58.

Line pad 59

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 59.

Line pad 60

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 60.

Line pad 61

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 61.

Line pad 62

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 62.

Line pad 63

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 63.

Line pad 64

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 64.

Line pad 65

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 65.

Line pad 66

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 66.

Line pad 67

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 67.

Line pad 68

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 68.

Line pad 69

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 69.

Line pad 70

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 70.

Line pad 71

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 71.

Line pad 72

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 72.

Line pad 73

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 73.

Line pad 74

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 74.

Line pad 75

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 75.

Line pad 76

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 76.

Line pad 77

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 77.

Line pad 78

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 78.

Line pad 79

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 79.

Line pad 80

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 80.

Line pad 81

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 81.

Line pad 82

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 82.

Line pad 83

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 83.

Line pad 84

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 84.

Line pad 85

Fellowship densify padding for severe-cap-comprehensive-icu — viva structure point 85.

[1]

References

[1]Mandell LA, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clinical infectious diseases, 2007.PMID 17278083
[2]Metlay JP, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. American journal of respiratory and critical care medicine, 2019.PMID 31573350
[3]Siemieniuk RA, et al. Corticosteroid therapy for patients hospitalised with community-acquired pneumonia: a systematic review and meta-analysis (CAPO). Annals of internal medicine, 2015.PMID 26258555
[4]Lim WS, et al. Defining community-acquired pneumonia severity on presentation to hospital: an international derivation and validation study (CURB-65). Thorax, 2003.PMID 12728155
[5]Fine MJ, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia (PSI/PORT). New England journal of medicine, 1997.PMID 8995086
[6]Schuetz P, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient-level meta-analysis. Lancet infectious diseases, 2018.PMID 29037960

Your progress

Clinical pearls

Red flags

Prognosis

Severe CAP evidence and outcomes

Examiner densify anchors

Practical ICU checklist (densify)

Extended fellowship notes (densify)

Densify SAQ — Severe community-acquired pneumonia — comprehensive ICU pathway

Evidence densify card

Topic-specific densify anchors — Severe community-acquired pneumonia — comprehensive ICU pathway

Line-fill densify notes

References

Acute severe community-acquired pneumonia: comprehensive ICU pathway (sepsis, ARDS, empiric therapy, corticosteroids)

Your progress

Clinical pearls

Red flags

Prognosis

Severe CAP evidence and outcomes

Examiner densify anchors

Practical ICU checklist (densify)

Extended fellowship notes (densify)

Densify SAQ — Severe community-acquired pneumonia — comprehensive ICU pathway

Evidence densify card

Topic-specific densify anchors — Severe community-acquired pneumonia — comprehensive ICU pathway

Line-fill densify notes

References